← Back to Search

Statins

A for Retinal Vein Occlusion (ATORVO Trial)

Phase 3
Waitlist Available
Led By Joel G Ray, MD MSc
Research Sponsored by University of Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

ATORVO Trial Summary

The ATORVO study is designed to determine whether atorvastatin (Lipitor) can improve vision, when compared to placebo

Eligible Conditions
  • Retinal Vein Occlusion
  • Blood Clot
  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion

ATORVO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference in improvement of at least 15 letters (3 lines) in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity in the affected eye at 24 weeks in patients on active treatment vs. placebo.
Secondary outcome measures
Composite of non-fatal myocardial infarction, hospitalization for acute coronary syndrome, receipt of coronary revascularization, stroke or death, by 52 weeks.
Mean change in The National Eye Institute 25-Item Visual Function Questionnaire-25 (VFQ-25) score from 0 to 24 weeks.
Mean change in the concentration of serum total cholesterol, LDL-cholesterol and highly sensitive C-reactive protein at 0 and 24 weeks.
+2 more

Side effects data

From 2014 Phase 3 trial • 58 Patients • NCT02084069
3%
Postoperative bleeding
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment
Control

ATORVO Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AExperimental Treatment1 Intervention
Atorvastatin 80 mg orally once daily for 24 weeks
Group II: PPlacebo Group1 Intervention
Placebo tablet orally once daily for 24 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atorvastatin
FDA approved

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,567 Previous Clinical Trials
10,911,693 Total Patients Enrolled
2 Trials studying Retinal Vein Occlusion
110 Patients Enrolled for Retinal Vein Occlusion
Unity Health TorontoOTHER
536 Previous Clinical Trials
447,349 Total Patients Enrolled
2 Trials studying Retinal Vein Occlusion
336 Patients Enrolled for Retinal Vein Occlusion
Ontario Association of OptometristsOTHER

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Atorvastatin for the Treatment of Retinal Vein Occlusion
2007. "Atorvastatin for the Treatment of Retinal Vein Occlusion". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00517257.
All > Branch Retinal Vein Occlusion > Lipitor
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top